By Josh White
Date: Wednesday 15 Nov 2023
(Sharecast News) - BiVictriX Therapeutics has received a patent grant from the Japanese Patent Office (JPO) for its lead asset BVX001, it announced on Wednesday.
By Josh White
Date: Thursday 12 Oct 2023
(Sharecast News) - Biotechnology company BiVictriX Therapeutics updated the market on the pre-clinical evaluation of BVX001 on Thursday - its first-in-class 'Bi-Cygni' antibody drug conjugate (ADC) developed for the potential treatment of acute myeloid leukaemia (AML).
By Josh White
Date: Tuesday 03 Oct 2023
(Sharecast News) - Biotechnology developer BiVictriX Therapeutics announced the appointment of Dr Adrian Howd as its chief financial officer (CFO) and chief business officer (CBO) on Tuesday.
Currency | UK Pounds |
Share Price | 11.25p |
Change Today | -0.50p |
% Change | -4.26 % |
52 Week High | 15.90 |
52 Week Low | 10.50 |
Volume | 14,569 |
Shares Issued | 82.53m |
Market Cap | £9.28m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
15:40 | 5 @ 10.50p |
15:25 | 5 @ 10.50p |
13:57 | 4,559 @ 11.55p |
You are here: research